[A case of advanced breast cancer with skin ulceration successfully treated with paclitaxel and toremifene therapy].
We report a case of advanced breast cancer with skin ulceration and bleeding (T4bN3bM0, Stage IIIC) achieving a significant improvement of QOL by paclitaxel (PTX) and toremifene (TOR) therapy. The patient was a 31-year-old woman who had ulcerative breast lump with skin ulcer. A core needle biopsy for breast tumor led to a diagnosis of an invasive ductal carcinoma positive for estrogen receptor and progesterone receptor, and negative for HER2/neu protein expression. She received 4 courses of tri-weekly CEF (C: 500 mg, E: 60 mg, F: 500 mg/m2/tri-weekly) and 4 courses of weekly PTX (80 mg/m2) with TOR (120 mg/day). The bleeding from the tumor disappeared after CEF chemotherapy. The response for breast tumor after PTX and TOR therapy was evaluated as partial response, and the infraclavicular, subpectoral, and interpectoral lymph nodes metastasis disappeared. Muscle-preserving radical mastectomy (Bt+Ax: Auchincloss) without skin transplantation were performed. She had no recurrence during one year after operation. PTX and TOR therapy were effective for advanced breast tumor, and can improve patient QOL and the clinical outcomes in Stage IIIC advanced breast cancer.
Sakurai
Kenichi
K
Division of Breast and Endocrine Surgery, Department of Surgery, Nihon University School of Medicine.
Fujisaki
Shigeru
S
Matsuo
Sadanori
S
Ogura
Michitaka
M
Enomoto
Katsuhisa
K
Kitajima
Akira
A
Tani
Mayumi
M
Amano
Sadao
S
Shiono
Motomi
M
D000328:Adult; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000150:complications / Q000188:drug therapy*; D018270:Carcinoma, Ductal, Breast / Q000150:complications / Q000188:drug therapy*; D005260:Female; D006470:Hemorrhage / Q000150:complications* / Q000209:etiology*; D006801:Humans; D009930:Organic Chemicals / Q000008:administration & dosage; D017239:Paclitaxel / Q000008:administration & dosage*; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis; D012883:Skin Ulcer / Q000209:etiology*
D000972:Antineoplastic Agents, Phytogenic; D009930:Organic Chemicals; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; C407785:tremifene; D017239:Paclitaxel